LB Pharmaceuticals Inc (LBRX)
NASDAQ: LBRX · Real-Time Price · USD
31.38
-0.43 (-1.35%)
At close: Apr 28, 2026, 4:00 PM EDT
31.38
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:04 PM EDT
Company Description
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
The company was incorporated in 2015 and is headquartered in New York, New York.
LB Pharmaceuticals Inc
| Country | United States |
| Founded | 2015 |
| IPO Date | Sep 11, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Heather Turner |
Contact Details
Address: One Pennsylvania Plaza, Suite 1025 New York, New York 10119 United States | |
| Phone | 212 605 0300 |
| Website | lbpharma.us |
Stock Details
| Ticker Symbol | LBRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001691082 |
| CUSIP Number | 50180M108 |
| ISIN Number | US50180M1080 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Zachary Prensky | Co-founder, Advisor to the Chief Executive Officer and Director |
| Heather D. Turner Esq., J.D. | Chief Executive Officer and Director |
| Gad Soffer | Chief Operating and Business Officer |
| Dr. Anna Eramo M.D. | Chief Medical Officer |
| Minako Pazdera J.D., Ph.D. | General Counsel |
| Lindsay Beaupre | Senior Vice President of People and Culture |
| Dr. Richard A. Silva Ph.D. | Senior Vice President of Technical Operations |
| Dr. James Rawls Pharm.D. | Senior Vice President of Regulatory Affairs |
| Ellen Rose | Senior Vice President of Corporate Affairs |
| Kaya Pai Panandiker Kamlesh | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2026 | ARS | Filing |
| Apr 23, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 14, 2026 | EFFECT | Notice of Effectiveness |
| Apr 14, 2026 | 424B3 | Prospectus |
| Apr 6, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Mar 26, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 26, 2026 | 10-K | Annual Report |
| Mar 26, 2026 | 8-K | Current Report |
| Mar 16, 2026 | 8-K | Current Report |